From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Coënon, Loïs, Villalba, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203678/
https://www.ncbi.nlm.nih.gov/pubmed/35720368
http://dx.doi.org/10.3389/fimmu.2022.913215
_version_ 1784728748901269504
author Coënon, Loïs
Villalba, Martin
author_facet Coënon, Loïs
Villalba, Martin
author_sort Coënon, Loïs
collection PubMed
description Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. The knowledge of the mechanism of action of CD16a gave rise to several strategies to improve ADCC, by working on either the mAbs or the NK cell. In this review, we give an overview of CD16a biology and describe the latest strategies employed to improve antibody-dependent NK cell cytotoxicity.
format Online
Article
Text
id pubmed-9203678
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92036782022-06-18 From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement Coënon, Loïs Villalba, Martin Front Immunol Immunology Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. The knowledge of the mechanism of action of CD16a gave rise to several strategies to improve ADCC, by working on either the mAbs or the NK cell. In this review, we give an overview of CD16a biology and describe the latest strategies employed to improve antibody-dependent NK cell cytotoxicity. Frontiers Media S.A. 2022-06-03 /pmc/articles/PMC9203678/ /pubmed/35720368 http://dx.doi.org/10.3389/fimmu.2022.913215 Text en Copyright © 2022 Coënon and Villalba https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Coënon, Loïs
Villalba, Martin
From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
title From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
title_full From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
title_fullStr From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
title_full_unstemmed From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
title_short From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
title_sort from cd16a biology to antibody-dependent cell-mediated cytotoxicity improvement
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203678/
https://www.ncbi.nlm.nih.gov/pubmed/35720368
http://dx.doi.org/10.3389/fimmu.2022.913215
work_keys_str_mv AT coenonlois fromcd16abiologytoantibodydependentcellmediatedcytotoxicityimprovement
AT villalbamartin fromcd16abiologytoantibodydependentcellmediatedcytotoxicityimprovement

Ejemplares similares